RT Journal Article
SR Electronic
T1 Epistasis regulates genetic control of cardiac hypertrophy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.06.23297858
DO 10.1101/2023.11.06.23297858
A1 Wang, Qianru
A1 Tang, Tiffany M.
A1 Youlton, Nathan
A1 Weldy, Chad S.
A1 Kenney, Ana M.
A1 Ronen, Omer
A1 Weston Hughes, J.
A1 Chin, Elizabeth T.
A1 Sutton, Shirley C.
A1 Agarwal, Abhineet
A1 Li, Xiao
A1 Behr, Merle
A1 Kumbier, Karl
A1 Moravec, Christine S.
A1 Wilson Tang, W. H.
A1 Margulies, Kenneth B.
A1 Cappola, Thomas P.
A1 Butte, Atul J.
A1 Arnaout, Rima
A1 Brown, James B.
A1 Priest, James R.
A1 Parikh, Victoria N.
A1 Yu, Bin
A1 Ashley, Euan A.
YR 2024
UL http://medrxiv.org/content/early/2024/05/05/2023.11.06.23297858.abstract
AB The combinatorial effect of genetic variants is often assumed to be additive. Although genetic variation can clearly interact non-additively, methods to uncover epistatic relationships remain in their infancy. We develop low-signal signed iterative random forests to elucidate the complex genetic architecture of cardiac hypertrophy. We derive deep learning-based estimates of left ventricular mass from the cardiac MRI scans of 29,661 individuals enrolled in the UK Biobank. We report epistatic genetic variation including variants close to CCDC141, IGF1R, TTN, and TNKS. Several loci where variants were deemed insignificant in univariate genome-wide association analyses are identified. Functional genomic and integrative enrichment analyses reveal a complex gene regulatory network in which genes mapped from these loci share biological processes and myogenic regulatory factors. Through a network analysis of transcriptomic data from 313 explanted human hearts, we found strong gene co-expression correlations between these statistical epistasis contributors in healthy hearts and a significant connectivity decrease in failing hearts. We assess causality of epistatic effects via RNA silencing of gene-gene interactions in human induced pluripotent stem cell-derived cardiomyocytes. Finally, single-cell morphology analysis using a novel high-throughput microfluidic system shows that cardiomyocyte hypertrophy is non-additively modifiable by specific pairwise interactions between CCDC141 and both TTN and IGF1R. Our results expand the scope of genetic regulation of cardiac structure to epistasis.Competing Interest StatementE.A.A. is a Founder of Personalis, Deepcell, Svexa, RCD Co, and Parameter Health; Advisor to Oxford Nanopore, SequenceBio, and Pacific Biosciences; and a non-executive director for AstraZeneca. C.S.W. is a consultant for Tensixteen Bio and Renovacor. V.N.P. is an SAB member for and receives research support from BioMarin, Inc, and is a consultant for Constantiam, Inc. and viz.ai. The remaining authors declare no competing interests.Funding StatementThis work was supported by the Chan Zuckerberg Biohub - San Francisco through the Intercampus Research Awards (2019 - 2022) to R.A., J.R.P., J.B.B., A.J.B., E.A.A., and B.Y. E.A.A. received funding from National Institutes of Health (NIH) through grant number 1R01HL144843. B.Y. received support from National Science Foundation (NSF) through grants DMS-1613002 and IIS 1741340, an NIH grant R01GM152718, and a Weill Neurohub grant. V.N.P. received funding from K08HL143185. T.M.T. was supported by the National Science Foundation (NSF) Graduate Research Fellowship Program DGE-2146752. Q.W. received funding from American Heart Association Postdoctoral Fellowship through grant number 23POST1023278. C.S.W. received support from NIH through grants F32HL160067 and L30HL159413.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of human subjects (IRB - 4237) and human-derived induced pluripotent stem cells (SCRO - 568) in this study has been approved by the Stanford Research Compliance Office. The UK Biobank received ethical approval from the North West - Haydock Research Ethics Committee (21/NW/0157).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll genotype and cardiac MRI data used as input to the lo-siRF pipeline are available from the UK Biobank (https://www.ukbiobank.ac.uk/). This work was conducted under the UK Biobank application 22282. GWAS-filtered SNVs using PLINK and BOLT-LMM are summarized in Extended Data 2. Data for the gene co-expression networks from 313 explanted human hearts is available at https://doi.org/10.5281/zenodo.2600420. All other data produced in this study are available upon reasonable request to the authors. https://yu-group.github.io/epistasis-cardiac-hypertrophy/